

SKYEPHARMA PLC
Form 6-K
November 03, 2005

**SECURITIES AND EXCHANGE COMMISSION
WASHINGTON, D.C. 20549**

FORM 6-K

**REPORT OF FOREIGN PRIVATE ISSUER
PURSUANT TO RULE 13a - 16 OR 15d - 16 OF
THE SECURITIES EXCHANGE ACT OF 1934**

For the month of November, 2005

SkyePharma PLC

(Translation of registrant's name into English)

SkyePharma PLC, 105 Piccadilly, London W1J 7NJ England

(Address of principal executive office)

Indicate by check mark whether the registrant files or will file annual reports under cover of Form 20-F or Form 40F.

Form 20-F Form 40-F

Indicate by check mark whether the registrant by furnishing the information contained in this Form is also thereby furnishing the information to the Commission pursuant to Rule 12g3-2(b) under the Securities Exchange Act of 1934.

Yes No

If "Yes" is marked, indicate below the file number assigned to the registrant in connection with Rule 12g3-2(b): 82-

Edgar Filing: SKYEPHARMA PLC - Form 6-K

SkyePharma PLC ("the Company") Notification of Interests of Directors

The Company has been informed of the following transactions by directors in respect of the Ordinary Shares issued in 2005 under the Company's rights issue:

Mr Michael Ashton has acquired a beneficial interest in 115,651 Ordinary Shares at a price of 30 pence per share. As a result of this transaction, Mr Ashton now has a beneficial interest in 686,610 Ordinary Shares in the Company.

Sir Michael Beavis has acquired a beneficial interest in 62,059 Ordinary Shares at a price of 30 pence per share. As a result of this transaction, Sir Michael now has a beneficial interest in 372,356 Ordinary Shares in the Company.

Mr Alan Bray has acquired a beneficial interest in 20,000 Ordinary Shares at a price of 30 pence per share. As a result of this transaction, Mr Bray now has a beneficial interest in 120,000 Ordinary Shares in the Company.

Dr David Ebsworth has acquired a beneficial interest in 18,000 Ordinary Shares at a price of 30 pence per share. As a result of this transaction, Dr Ebsworth now has a beneficial interest in 108,000 Ordinary Shares in the Company.

Mr Ian Gowrie-Smith has acquired a beneficial interest in a total of 331,706 Ordinary Shares as a result of the following transactions: Walkvale Limited, a company in which Mr Ian Gowrie-Smith has a beneficial interest, has sold 232,500 nil-paid rights at a price of 5.25 pence per right and acquired 35,643 Ordinary Shares in Estuary Investments Limited, a company in which Mr Ian Gowrie-Smith has a beneficial interest, at a price of 5.25 pence per share; Mr Ian Gowrie-Smith has acquired 128,650 Ordinary Shares at a price of 30 pence per share in a company in which Mr Ian Gowrie-Smith has a beneficial interest; Mr Ian Gowrie-Smith has acquired 98,972 Ordinary Shares in Thornaby Limited, a company in which Mr Ian Gowrie-Smith has a beneficial interest, at a price of 30 pence per share; Mr Ian Gowrie-Smith has sold 80,000 Ordinary Shares at a price of 30 pence per share and acquired 20,000 Ordinary Shares at a price of 30 pence per share. Mr Ian Gowrie-Smith now has a beneficial interest in 48,441 Ordinary Shares at a price of 30 pence per share.

As a result of these transactions, Mr Gowrie-Smith now has a beneficial interest in 7,452,744 Ordinary Shares in the Company.

Mr Stephen Harris has acquired a beneficial interest in 26,216 Ordinary Shares at a price of 30 pence per share. As a result of this transaction, Mr Harris now has a beneficial interest in 157,299 Ordinary Shares in the Company.

Dr Keith Mansford has acquired a beneficial interest in 13,588 Ordinary Shares at a price of 30 pence per share. As a result of this transaction, Dr Mansford now has a beneficial interest in 81,531 Ordinary Shares in the Company.

Mr Donald Nicholson has acquired a beneficial interest in 109,961 Ordinary Shares at a price of 30 pence per share. As a result of this transaction, Mr Nicholson now has a beneficial interest in 752,467 Ordinary Shares in the Company.

END

SIGNATURES

Pursuant to the requirements of the Securities Exchange Act of 1934, the registrant has duly caused this report to be signed on its behalf by the undersigned, thereunto duly authorized.

SkyePharma PLC

By: /s/ Douglas Parkhill

Name: Douglas Parkhill
Title: Company Secretary

Date: November 3, 2005